https://www.zonebourse.com/cours/action/ANAPTYSBIO-INC-33634949/actualite/Jemperli-dostarlimab-gxly-agent-immuno-oncologique-associe-a-GSK-approuve-aux-Etats-Unis-pou-44482867/?utm_source=telegram&utm_medium=social&utm_campaign=share